Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - Repository

Full text

: https://doi.org/10.1038/s41467-023-43644-x

Abstract

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome.

Rights

Copyright © The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Cite as

RECOVERY Collaborative Group, Peto, L., Staplin, N., Campbell, M., Pessoa-Amorim, G., Mafham, M., Emberson, J., Stewart, R., Prudon, B., Uriel, A., Green, C., Dhasmana, D., Malein, F., Majumdar, J., Collini, P., Shurmer, J., Yates, B., Baillie, J., Buch, M., Day, J., Faust, S., Jaki, T., Jeffery, K., Juszczak, E., Knight, M., Lim, W., Montgomery, A., Mumford, A., Rowan, K., Thwaites, G., Haynes, R., Landray, M. & Horby, P. 2024, 'Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial', Nature Communications, 15, article no: 924. https://doi.org/10.1038/s41467-023-43644-x

Downloadable citations

HTML BIB RIS

Identifiers

DOI: https://doi.org/10.1038/s41467-023-43644-x

Repository URI: http://hdl.handle.net/10023/29140